针对大脑的布里瓦拉塞坦使用曼诺斯功能化的半孔化纳米颗粒用于治疗
Sumit Patel1, Mustakim Mansuri1, Ishani Mehta1
1L. M. College of Pharmacy, Opposite Gujarat University, Navrangpura, Ahmedabad, Gujarat 380009, India.
Brain research
|March 6, 2026
概括
表面工程的半孔纳米颗粒 (MSN) 提供了对的布里瓦拉塞坦 (BVM) 控制释放. 曼诺结合的MSN在体内证明增强了大脑输送和改善了控制.
科学领域:
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
- 制药科学 制药科学
背景情况:
- 治疗需要有效的药物输送到大脑.
- 半孔纳米粒子 (MSN) 被探索为药物载体.
- 控制和有针对性的输送系统对于提高治疗疗效至关重要.
研究的目的:
- 开发表面工程化半孔纳米颗粒 (MSN) 用于控制释放布里瓦拉塞坦 (BVM).
- 评估这些MSN在症中向大脑输送的潜力.
- 评估体外药物释放特征和体内药学动力学效应.
主要方法:
- 通过使用TEOS和CTAB修改的sol-gel工艺合成的MSN.
- 使用APTES进行表面功能化,随后涂上酸盐涂层.
- 与D-曼诺结合,用于有针对性的输送.
- 布里瓦拉 (BVM) 通过物理吸附加载.
- 在体外药物释放研究和体内药学动力学评估使用最大电击 (MES) 模型.
主要成果:
- 与立即释放相比,MSN配方在48小时内表现出持续的BVM释放.
- 曼诺结合的MSN显示持续释放特征与科尔斯迈耶-佩帕斯模型一致.
- 在体内研究表明,BVM装载的MSN显著减少了发作.
- 与非结合的MSN (18.46%的减少) 相比,与曼诺结合的BVM装载的MSN提供了更高的抗活性 (23.07%的减少).
结论:
- 表面工程MSN是持续布里瓦拉塞坦递送的有效载体.
- 曼诺结合增强了针对性脑部输送和抗疗效.
- 这些功能化的MSN显示出改善治疗中发作控制的希望.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
67
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
67
01:24Modified-Release Drug Delivery Systems: Site-Targeted
59
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
59
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K